Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 [Yahoo! Finance]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Yahoo! Finance
company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14. The event will include Joseph A. Murray, M.D., professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology at the Mayo Clinic, along with members of the Anaptys management team. The event will cover: ANB033's mechanism of action, an antagonist of the CD122 receptor Preclinical data and initial Phase 1a data in healthy volunteers Celiac disease (CeD) disease biology and Phase 1b trial design The event will be followed by a Q&A session. A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events . A replay of the webcast will be available following the event. About ANB033 ANB033, a potentially best-in-class CD122
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]Yahoo! Finance
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion SicknessPR Newswire
- Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VNDA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness [Yahoo! Finance]Yahoo! Finance
VNDA
Earnings
- 10/29/25 - Miss
VNDA
Sec Filings
- 12/4/25 - Form 8-K
- 11/28/25 - Form 8-K
- 10/30/25 - Form 10-Q
- VNDA's page on the SEC website